BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $570 from $595 and keeps a Neutral rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings “may not have the same impact they’ve had in prior years,” the analyst tells investors in a preview for the firm’s biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche
- Madrigal Pharmaceuticals initiated with an Overweight at Barclays
- Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
- Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
- Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen